Log In
Print
BCIQ
Print
Print this Print this
 

Tasigna, nilotinib

Also known as: formerly AMN107

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionBCR-ABL tyrosine kinase inhibitor
Molecular Target BCR-ABL tyrosine kinase
Mechanism of ActionBCR-ABL tyrosine kinase inhibitor
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today